** Shares of gene therapy makers and developers slide premarket after WSJ and other media outlets report that Peter Marks, a top official at the US FDA, has been pushed out of the agency
** Marks was the head of FDA's Center for Biologics Evaluation and Research (CBER) and introduced several programs to accelerate the development of gene and cell therapies during his tenure
** Taysha Gene Therapies TSHA.O down 10.9% at $1.72 premarket, Solid Biosciences SLDB.O down 7.2% at $4.01, US-listed shares of CRISPR Therapeutics CRSP.O down 3.8% at $35.60
** "Gene and cell therapies likely under increased pressure, given CBER and Marks' intimate relationship with many of these companies and programs," says BMO Capital Markets analyst Evan Seigerman
** Marks did not respond to Reuters' request for comment
** Marks was given the choice by a Health and Human Services official to resign or be fired, according to WSJ, which also reported that his resignation is effective April 5
(Reporting by Manas Mishra)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。